论著

云南省输入性间日疟原虫多药抗性蛋白1基因突变多态性分析

  • 丁红芸 ,
  • 董莹 ,
  • 徐艳春 ,
  • 邓艳 ,
  • 刘言 ,
  • 吴静 ,
  • 陈梦妮 ,
  • 张苍林
展开
  • 1 昆明理工大学生命科学与技术学院,云南昆明 650500
    2 云南省寄生虫病防治所,云南省疟疾研究中心,云南省虫媒传染病防控研究重点实验室,普洱 665000
丁红芸(1998-),女,硕士研究生,从事疟疾的分子流行病学研究。E-mail:1053343328@qq.com
*董莹(1964-),女,本科,主任医师,从事疟疾病原学及分子生物学研究。E-mail:luxidongying@126.com

收稿日期: 2022-10-13

  修回日期: 2023-01-27

  网络出版日期: 2023-09-06

基金资助

国家自然科学基金(81660559);国家自然科学基金(82160637)

Polymorphism analysis of multidrug resistance protein 1 gene in imported Plasmodium vivax in Yunnan Province

  • DING Hongyun ,
  • DONG Ying ,
  • XU Yanchun ,
  • DENG Yan ,
  • LIU Yan ,
  • WU Jing ,
  • CHEN Mengni ,
  • ZHANG Canglin
Expand
  • 1 Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, Yunnan, China
    2 Yunnan Institute of Parasitic Diseases, Yunnan Center of Malaria Research, Yunnan Provincial Key Laboratory of Vector-borne Diseases Control and Research, Puer 665000, China

Received date: 2022-10-13

  Revised date: 2023-01-27

  Online published: 2023-09-06

Supported by

National Natural Science Foundation of China(81660559);National Natural Science Foundation of China(82160637)

摘要

目的 分析云南省输入性间日疟原虫的多药抗性蛋白1基因(Pvmdr1)突变多态性。 方法 对云南省2020年和2021年诊断为间日疟原虫感染的病例血样进行Pvmdr1全基因扩增及测序,以间日疟原虫Sal-Ⅰ分离株的序列(GenBank登录号:NC_009915.1)为模板设计PCR反应引物,用MEGA 5.04软件与编码区参比序列(GenBank登录号:XM_001613678.1)进行比对,用DnaSP 6.11.01软件分析单倍型和单核苷酸多态(SNP)位点及其突变类型,并计算核酸多样性指数π、单倍型期望杂合度(He)等,用Network 10.0软件构建中介网络进化图。 结果 共收集276份输入性间日疟患者血样,其中自缅甸感染病例占99.3%(274/276),自非洲、巴基斯坦感染各占0.4%(1/276)。259份血样扩增获得4 392 bp的Pvmdr1全基因序列,提交GenBank获得的登录号为OP559204~OP559462。259条DNA序列π、Ka/Ks比值分别为0.000 76和3.600 6,共检出22个SNP,包括13个非同义突变和9个同义突变。仅c.4074C>T位点突变在2020、2021年的检出率[15.0%(21/140)、5.9%(7/119)]差异有统计学意义(χ2 = 5.546,P < 0.05)。次等位位点为c.1587A>G(97.9%,253/259),新检出SNP包括c.2499G>T(2.3%,6/259)、c.3358C>T(0.4%,1/259)、c.3832C>T(0.4%,1/259)。c.3064C>T、c.4065A>G、c.3358C>T和c.3832C>T突变位点仅在2021年的患者血样中检出,其中前2个SNP从非洲感染的分离株中检出,后2个SNP从缅甸感染的分离株中检出。259条Pvmdr1完整编码区与参比序列(单倍型Hap_1)比对,识别出26种单倍型(Hap_2~Hap_27),均为参比序列(单倍型Hap_1)的突变型,He为0.890 7。其中,Hap_8的检出率最高(18.5%,48/259),非洲感染分离株中仅检出Hap_19。2020、2021年的患者血样中检出的单倍型种类分别有15和22种,当年独有的单倍型分别为4和10种。Hap_10在2020、2021年患者血样中的检出率分别为15.0%(21/140)和3.4%(4/119),差异有统计学意义(χ2 = 22.264,P < 0.05)。不同单倍型的多重突变识别结果显示,4重、5重、6重、7重、9重、10重突变在26种单倍型中的占比分别为0.4%(1/26)、19.2%(5/26)、38.5%(10/26)、30.8%(8/26)、0.4%(1/26)、0.4%(1/26)。中介网络图显示,26种单倍型以单倍型Hap_1为起始,经4重突变(Hap_24),向5重、6重、7重、9重和10重突变逐级进化并远离起始点。 结论 云南省输入性间日原虫Pvmdr1基因突变存在高度多态性。

本文引用格式

丁红芸 , 董莹 , 徐艳春 , 邓艳 , 刘言 , 吴静 , 陈梦妮 , 张苍林 . 云南省输入性间日疟原虫多药抗性蛋白1基因突变多态性分析[J]. 中国寄生虫学与寄生虫病杂志, 2023 , 41(4) : 404 -411 . DOI: 10.12140/j.issn.1000-7423.2023.04.002

Abstract

Objective To analyze the polymorphism of Plasmodium vivax multidrug resistance protein 1 gene (Pvmdr1) from imported vivax malaria patients in Yunnan Province. Methods The whole Pvmdr1 gene was amplified and sequenced in the blood samples of patients who diagnosed with vivax malaria in 2020 and 2021 in Yunnan Province. The sequence of P. vivax SalⅠ isolate (GenBank accession number: NC_009915.1) was taken as the reference sequence for designing primers. MEGA 5.04 software was used to align the spliced sequences with the coding region reference sequence (GenBank accession number: XM_001613678.1). Haplotype and single nucleotide polymorphism (SNP) sites and their mutation types, nucleotide diversity π, expected heterozygosity (He), etc were analyzed by DnaSP 6.11.01. Haplotype medium network diagram was constructed using Network 10.0 Software. Results A total of 276 blood samples were collected from vivax malaria patients and were imported from overseas. The full gene sequences with 4 392 bp of Pvmdr1 were obtained from 259 blood samples, and the accession numbers were OP559204-OP559462 assigned by GenBank. The π of 259 DNA coding sequences was 0.000 76. A total of 22 SNPs were detected from 259 coding sequences, including 13 non-synonymous mutant and 9 synonymous mutant loci. Only the detection rate difference of c.4074C>T mutation between 2020 and 2021 [15.0% (21/140), 5.9% (7/119)] was statistically significant (χ2 = 5.546, P < 0.05). The minor allele frequency was c.1587A>G (97.9%, 253/259), and the newly discovered SNPs included c.2499G>T (2.3%, 6/259), c.3358C>T (0.4%, 1/259), and c.3832C>T (0.4%, 1/259). All of c.3064C>T, c.4065A>G, c.3358C>T and c.3832C>T mutant sites were detected from the blood samples in 2021. The 259 complete coding region sequences of Pvmdr1 were defined as 26 haplotypes (Hap_2-Hap_27) by comparison with the reference sequence (haplotype Hap_1, all of which were mutant type haplotypes, and He was 0.890 7. Among them, the detection rate of Hap_8 was the highest (18.5%, 48/259). There were 15 and 22 haplotypes found from blood samples in 2020 and 2021, respectively. Among them, 4 haplotypes were only detected in blood samples from 2020, and 10 haplotype were only detected in blood samples from 2021. The difference of Hap_10 detection rate between 2020 and 2021 [15.0% (21/140), 3.4% (4/119)] was statistically significant (χ2 = 22.264, P < 0.05). The proportions of quadruple, quintuple, six-fold, seven-fold, nine-fold and ten-fold multiple mutations in 26 haplotypes were 0.4% (1/26), 19.2% (5/26), 38.5% (10/26), 30.8% (8/26), 0.4% (1/26), and 0.4% (1/26), respectively. The haplotype medium network diagram displayed that the gradual evolution of 26 haplotypes started with Hap_1, and then passed through quadruple mutation (Hap_24), moved towards quintuple, six-fold, seven-fold, nine-fold, and ten-fold multiple mutations away from. Conclusion There is high polymorphism in the Pvmdr1 gene in the P. vivax from the imported vivax malaria cases in Yunnan Province.

参考文献

[1] Xia ZG, Feng J, Zhang L, et al. Achieving malaria elimination in China: analysis on implementation and effectiveness of the surveillance-response system[J]. Chin J Parasitol Parasit Dis, 2021, 39(6): 733-741. (in Chinese)
  (夏志贵, 丰俊, 张丽, 等. 中国消除疟疾: 监测响应系统的实施与成效分析[J]. 中国寄生虫学与寄生虫病杂志, 2021, 39(6): 733-741.)
[2] Zhang L, Feng J, Zhang SS, et al. Epidemiological characteristics of malaria in China, 2016[J]. Chin J Parasitol Parasit Dis, 2017, 35(6): 515-519. (in Chinese)
  (张丽, 丰俊, 张少森, 等. 2016年全国疟疾疫情特征分析[J]. 中国寄生虫学与寄生虫病杂志, 2017, 35(6): 515-519.)
[3] Zhang L, Yi BY, Xia ZG, et al. Epidemiological characteristics of malaria in China, 2021[J]. Chin J Parasitol Parasit Dis, 2022, 40(2): 135-139. (in Chinese)
  (张丽, 易博禹, 夏志贵, 等. 2021年全国疟疾疫情特征分析[J]. 中国寄生虫学与寄生虫病杂志, 2022, 40(2): 135-139.)
[4] Rieckmann KH, Davis DR, Hutton DC. Plasmodium vivax resistance to chloroquine?[J]. Lancet, 1989, 334(8673): 1183-1184.
[5] (Myat-Phone-Kyaw, Myint-Oo, Myint-Lwin, et al. Emergence of chloroquine-resistant Plasmodium vivax in Myanmar (Burma)[J]. Trans R Soc Trop Med Hyg, 1993, 87(6): 687.
[6] Singh RK. Emergence of chloroquine-resistant vivax malaria in South Bihar (India)[J]. Trans R Soc Trop Med Hyg, 2000, 94(3): 327.
[7] Phan GT, de Vries PJ, Tran BQ, et al. Artemisinin or chloroquine for blood stage Plasmodium vivax malaria in Vietnam[J]. Trop Med Int Health, 2002, 7(10): 858-864.
[8] Musset L, Heugas C, Naldjinan R, et al. Emergence of Plasmodium vivax resistance to chloroquine in French Guiana[J]. Antimicrob Agents Chemother, 2019, 63(11): e02116-e02118.
[9] Picot S, Brega S, Gér?me P, et al. Absence of nucleotide polymorphism in a Plasmodium vivax multidrug resistance gene after failure of mefloquine prophylaxis in French Guyana[J]. Trans R Soc Trop Med Hyg, 2005, 99(3): 234-237.
[10] Marfurt J, de Monbrison F, Brega S, et al. Molecular markers of in vivo Plasmodium vivax resistance to amodiaquine plus sulfadoxine-pyrimethamine: mutations in Pvdhfr and Pvmdr1[J]. J Infect Dis, 2008, 198(3): 409-417.
[11] Zeng WL, Zhao H, Zhao W, et al. Molecular surveillance and Ex vivo drug susceptibilities of Plasmodium vivax isolates from the China-Myanmar border[J]. Front Cell Infect Microbiol, 2021, 11: 738075.
[12] Li JY, Zhang J, Li Q, et al. Ex vivo susceptibilities of Plasmodium vivax isolates from the China-Myanmar border to antimalarial drugs and association with polymorphisms in Pvmdr1 and Pvcrt-o genes[J]. PLoS Negl Trop Dis, 2020, 14(6): e0008255.
[13] Xu SL, Zeng WL, Ngassa Mbenda HG, et al. Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: a prospective open-label efficacy trial[J]. Travel Med Infect Dis, 2020, 36: 101499.
[14] Ratcliff A, Siswantoro H, Kenangalem E, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia[J]. Trans R Soc Trop Med Hyg, 2007, 101(4): 351-359.
[15] Ganguly S, Saha P, Guha SK, et al. In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in Pvmdr1 and Pvcrt-o genes[J]. Antimicrob Agents Chemother, 2013, 57(3): 1246-1251.
[16] Pukrittayakamee S, Imwong M, Looareesuwan S, et al. Therapeutic responses to antimalarial and antibacterial drugs in vivax malaria[J]. Acta Trop, 2004, 89(3): 351-356.
[17] Wang ZS, Wei CY, Pan YC, et al. Polymorphisms of potential drug resistant molecular markers in Plasmodium vivax from China-Myanmar border during 2008—2017[J]. Infect Dis Poverty, 2022, 11: 43.
[18] WHO. Malaria surveillance, monitoring & evaluation: a reference manua[M]. Geneva: WHO, 2018: 69-81.
[19] Chung DI, Jeong S, Dinzouna-Boutamba SD, et al. Evaluation of single nucleotide polymorphisms of Pvmdr1 and microsatellite genotype in Plasmodium vivax isolates from Republic of Korea military personnel[J]. Malar J, 2015, 14: 336.
[20] Nomura T, Carlton JM, Baird JK, et al. Evidence for different mechanisms of chloroquine resistance in 2 Plasmodium species that cause human malaria[J]. J Infect Dis, 2001, 183(11): 1653-1661.
[21] Sá JM, Nomura T, Neves JD, et al. Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains[J]. Exp Parasitol, 2005, 109(4): 256-259.
[22] Carlton J. The Plasmodium vivax genome sequencing project[J]. Trends Parasitol, 2003, 19(5): 227-231.
[23] Walliker D, Quakyi IA, Wellems TE, et al. Genetic analysis of the human malaria parasite Plasmodium falciparum[J]. Science, 1987, 236(4809): 1661-1666.
[24] McConkey GA, Waters AP, McCutchan TF. The generation of genetic diversity in malaria parasites[J]. Annu Rev Microbiol, 1990, 44: 479-498.
[25] Ngassa Mbenda HG, Wang ML, Guo J, et al. Evolution of the Plasmodium vivax multidrug resistance 1 gene in the Greater Mekong Subregion during malaria elimination[J]. Parasit Vectors, 2020, 13(1): 67.
[26] Kittichai V, Nguitragool W, Ngassa Mbenda HG, et al. Genetic diversity of the Plasmodium vivax multidrug resistance 1 gene in Thai parasite populations[J]. Infect Genet Evol, 2018, 64: 168-177.
[27] Villena FE, Magui?a JL, Santolalla ML, et al. Molecular surveillance of the Plasmodium vivax multidrug resistance 1 gene in Peru between 2006 and 2015[J]. Malar J, 2020, 19(1): 450.
[28] Cubides JR, Camargo-Ayala PA, Ni?o CH, et al. Simultaneous detection of Plasmodium vivax dhfr, dhps, mdr1 and crt-o resistance-associated mutations in the Colombian Amazonian region[J]. Malar J, 2018, 17(1): 130.
[29] Huang F, Li SG, Tian P, et al. Genetic polymorphisms in genes associated with drug resistance in Plasmodium vivax parasites from northeastern Myanmar[J]. Malar J, 2022, 21(1): 66.
[30] Orjuela-Sánchez P, de Santana Filho FS, Machado-Lima A, et al. Analysis of single-nucleotide polymorphisms in the crt-o and mdr1 genes of Plasmodium vivax among chloroquine-resistant isolates from the Brazilian Amazon region[J]. Antimicrob Agents Chemother, 2009, 53(8): 3561-3564.
[31] Tacoli C, Gai PP, Siegert K, et al. Characterization of Plasmodium vivax Pvmdr1 polymorphisms in isolates from mangaluru, India[J]. Am J Trop Med Hyg, 2019, 101(2): 416-417.
[32] Diez Benavente E, Ward Z, Chan W, et al. Genomic variation in Plasmodium vivax malaria reveals regions under selective pressure[J]. PLoS One, 2017, 12(5): e0177134.
[33] Imwong M, Pukrittayakamee S, Pongtavornpinyo W, et al. Gene amplification of the multidrug resistance 1 gene of Plasmodium vivax isolates from Thailand, Laos, and Myanmar[J]. Antimicrob Agents Chemother, 2008, 52(7): 2657-2659.
[34] González-Cerón L, Montoya A, Corzo-Gómez JC, et al. Genetic diversity and natural selection of Plasmodium vivax multi-drug resistant gene (Pvmdr1) in Mesoamerica[J]. Malar J, 2017, 16(1): 261.
[35] Zhao Y, Wang L, Soe MT, et al. Molecular surveillance for drug resistance markers in Plasmodium vivax isolates from symptomatic and asymptomatic infections at the China-Myanmar border[J]. Malar J, 2020, 19(1): 281.
[36] Lu F, Lim CS, Nam DH, et al. Genetic polymorphism in Pvmdr1 and Pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries[J]. Acta Trop, 2011, 117(2): 69-75.
[37] Barnadas C, Ratsimbasoa A, Tichit M, et al. Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in Pvmdr1 and Pvcrt-o genes[J]. Antimicrob Agents Chemother, 2008, 52(12): 4233-4240.
文章导航

/

〈 〉